CureVac NV (CVAC)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$4.66

+0.00 (+0.00%)

Market Cap: $1.05B

Last updated: Nov 05, 2026 at 4:00 PM ET

Earnings

Performance (10Y)

Beat Rate

64%(14/22)

Avg Surprise

-12.28%

Streak

2 Q

Last 12 of 22 reported quarters

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Mar 31, 2026Mar 26 Reported Apr 29, 2026Reported Apr 29	$0.00	N/A	-	+100.00%	Beat	-	-	+100.0%
Sep 30, 2025Sep 25 Reported Nov 24, 2025Reported Nov 24	$-0.07	N/A	-	+53.33%	Beat	2	1 0 30d	-104.7%
Jun 30, 2025Jun 25 Reported Aug 15, 2025Reported Aug 15	$-0.26	$-0.05	$-0.08 - $-0.01	-466.45%	Miss	2	0 1 30d	+25.3%
Mar 31, 2025Mar 25 Reported Apr 10, 2025Reported Apr 10	$-0.16	$-0.19	$-0.19 - $-0.19	+17.65%	Beat	1	0 1 30d	+60.1%
Dec 31, 2024Dec 24 Reported Dec 31, 2024Reported Dec 31	$-0.14	$-0.09	$-0.12 - $-0.03	-54.19%	Miss	3	1 0 30d	+66.7%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$1.50	$0.61	$-0.31 - $1.60	+145.90%	Beat	4	No revisions (30d)	+781.8%
Jun 30, 2024Jun 24 Reported Aug 15, 2024Reported Aug 15	$-0.35	$-0.26	$-0.40 - $-0.20	-33.92%	Miss	6	No revisions (30d)	-16.1%
Mar 31, 2024Mar 24 Reported Apr 24, 2024Reported Apr 24	$-0.39	$-0.18	$-0.34 - $-0.14	-116.67%	Miss	5	1 0 30d	-44.4%
Dec 31, 2023Dec 23 Reported Mar 12, 2024Reported Mar 12	$-0.42	$-0.20	$-0.33 - $-0.11	-110.00%	Miss	6	No revisions (30d)	+36.4%
Sep 30, 2023Sep 23 Reported Nov 14, 2023Reported Nov 14	$-0.22	$-0.23	$-0.34 - $-0.18	+4.35%	Beat	4	No revisions (30d)	+12.0%
Jun 30, 2023Jun 23 Reported Aug 17, 2023Reported Aug 17	$-0.30	$-0.24	$-0.29 - $-0.21	-25.00%	Miss	5	No revisions (30d)	+3.2%
Mar 31, 2023Mar 23 Reported Apr 27, 2023Reported Apr 27	$-0.27	$-0.34	$-0.55 - $-0.27	+20.59%	Beat	3	No revisions (30d)	-237.5%

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	-7.85x	FCF Yield	-12.73%
Profitability
Profit Margin	182.10%	Operating Margin	573.00%
ROE	40.20%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	3.70x	Quick Ratio	3.69x
Trading Statistics
Beta	1.84	Avg Volume	N/A
52-Week High	$5.55	52-Week Low	$4.00

Technical Indicators Dashboard

Moving Averages

SMA 10$4.66

SMA 20$4.66

SMA 50$4.66

SMA 200$4.64

EMA 10$4.66

EMA 20$4.66

EMA 50$4.66

EMA 200$4.68

MACD

Line: N/ASignal: N/AHist: N/A

ADX

ADX: 7.1+DI: 25.8-DI: 29.7

Aroon & PSAR

Aroon Up100.0

Aroon Down100.0

PSAR$4.66

Bollinger Bands

Upper Band$4.66

Lower Band$4.66

%B PositionN/A

Band Width0.50

RSI (14-Day)

Neutral

48.0

Momentum Oscillators

Stoch %KN/A

Stoch %DN/A

Williams %RN/A

ROC (10d)N/A

MomentumN/A

CCI (20d)N/A

MFI (14d)N/A

Volatility Measures

ATR (14d)N/A

StdDev (20d)N/A

Hist VolN/A

Volume Flow

VWAP$4.66

OBV11.1M

AD Line9.2M

CMF (20d)N/A

Volume Metrics

Avg Vol (20d)N/A

Vol RatioN/A

VWMA (20d)N/A

Pivot Points

R3$4.66

R2$4.66

R1$4.66

Pivot Point$4.66

S1$4.66

S2$4.66

S3$4.66

Advanced Oscillators

TSI-2.35

Ultimate OscN/A

KSTN/A

Financial Data

Quarter	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022
Total Revenue	$493.90M	$1.25M	$893,000	$14.47M	$493.90M	$14.44M	$12.37M	$22.57M	$16.48M	$7.58M	$7.13M	$11.69M
Cost of Revenue	$-21,931,000	$2.21M	$875,000	$1.49M	$21.93M	$40.72M	$41.69M	$53.60M	$24.28M	$25.85M	$20.64M	$80.00M
Gross Profit	$472.97M	$-968,000	$18,000	$12.98M	$471.97M	$-26,287,000	$-29,316,000	$-31,030,000	$-7,798,000	$-18,275,000	$-13,506,000	$-68,312,000

Operating Expenses	$-32,612,000	$60.78M	$54.74M	$55.46M	$103.59M	$47.33M	$44.92M	$111.68M	$46.71M	$53.70M	$47.16M	$53.67M
R&D	$49.98M	$34.88M	$37.59M	$44.14M	$49.98M	$31.09M	$27.82M	$33.36M	$27.25M	$30.87M	$24.25M	$27.62M
SG&A	$25.43M	$21.39M	$16.41M	$16.34M	$14.06M	$13.37M	$16.69M	$21.68M	$15.84M	$18.98M	$19.60M	$23.57M
Operating Income	$368.38M	$-61,746,000	$-54,727,000	$-40,988,000	$368.38M	$-73,620,000	$-73,317,000	$-89,109,000	$-54,036,000	$-71,801,000	$-60,355,000	$-121,510,000

Interest Income	$3.29M	$2.34M	$3.40M	$3.72M	$2.33M	$2.53M	$3.77M	$2.80M	$9.45M	$6.20M	$3.89M	$6.61M
Interest Expense	$6.92M	$565,000	$333,000	$636,000	$141,000	$155,000	$340,000	$4.33M	$4.08M	$1.78M	$951,000	$630,000
Income Before Tax	$370.57M	$-59,966,000	$-51,655,000	$-38,561,000	$370.57M	$-71,243,000	$-69,887,000	$-86,488,000	$-48,675,000	$-67,387,000	$-57,418,000	$-128,750,000
Income Tax Expense	$-32,529,000	$-406,000	$429,000	$0	$32.53M	$1.30M	$666,000	$0	$6,000	$26,000	$1,000	$34,000

Net Income	$338.04M	$-59,560,000	$-52,084,000	$-32,761,000	$338.04M	$-72,543,000	$-70,553,000	$-86,653,000	$-48,681,000	$-67,414,000	$-57,419,000	$-128,784,000

EBITDA	N/A	$-54,993,000	$-46,745,000	N/A	$375.23M	$-65,962,000	$-64,417,986	N/A	$-38,308,458	$-59,968,000	$-50,526,173	$-126,381,000
EBIT	N/A	$-59,401,000	$-51,322,000	N/A	$370.71M	$-71,088,000	$-69,547,000	N/A	$-44,590,000	$-65,758,237	$-56,467,000	$-121,510,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CVAC

News

CureVac stock converts into BioNTech shares after merger

CureVac stock has converted into BioNTech shares following a completed merger, with shareholders receiving 0.0520 BNTX shares for each CVAC share. This acquisition, initially valued at $1.25 billion in June 2025...

AD HOC NEWS•Oct 4, 2026 4:05 AM ET10/4/26•Bearish

CureVac stock enters a new chapter after BioNTech takeover

CureVac stock is entering a new phase following BioNTech's $1.25 billion all-stock acquisition, shifting its investment case from an independent biotech company to an asset controlled by BioNTech. The transaction...

AD HOC NEWS•Sep 25, 2026 6:06 AM ET9/25/26•Neutral

CureVac stock was delisted after its BioNTech merger

CureVac stock was delisted on January 9, 2026, following a merger with BioNTech, where each CVAC share was exchanged for 0.0520 BNTX shares. BioNTech is currently reviewing divestment options for CureVac's operating...

AD HOC NEWS•Sep 24, 2026 9:55 AM ET9/24/26•Bearish

CureVac stock holds near USD 3 as pipeline focus continues

CureVac N.V. (CVAC) stock closed at USD 3.00 on September 22, 2026, representing a 1.6% decline, and is trading within its 52-week range of USD 2.10 to USD 5.40. The biotechnology company reported H1 2026 revenue of EUR...

AD HOC NEWS•Sep 22, 2026 8:37 PM ET9/22/26•Somewhat-Bearish

CureVac stock holds near its yearly range as pipeline data guide trading

CureVac stock's performance on September 22, 2026, is primarily driven by its pipeline execution, with investors evaluating clinical development, regulatory milestones...

AD HOC NEWS•Sep 22, 2026 1:55 AM ET9/22/26•Neutral

CVAC Valuation and Fair Value

Forward P/E: 5.2x
P/FCF: -7.9x
P/B: 1.0x

See GNG's fair value

CVAC Profitability: Margins, ROIC and FCF

Gross margin: 95.0%
Operating margin: 573.0%
Net margin: 182.1%
ROE: 40.2%
FCF margin: -21.0%
FCF yield: -12.7%

CVAC Competitors

Company	Ticker
Si-Bone Inc	SIBN
Castle Biosciences Inc	CSTL
Integra LifeSciences Holdings	IART
Ventyx Biosciences Inc	VTYX
Iradimed Co	IRMD
QuidelOrtho Corp	QDEL
Verastem Inc	VSTM
MoonLake Immunotherapeutics	MLTX

Sector: Healthcare

CVAC Bull Case vs Bear Case

Bull case

CVAC has a 182.1% net profit margin.

Bear case

CVAC's quarterly revenue changed -89.0% year over year.

CVAC Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: -44.3%

CVAC Earnings Call

The latest CVAC earnings call transcript on file is labeled 2024Q3.

Read the 2024Q3 transcript

Frequently Asked Questions About CVAC

Does CVAC pay dividends?

CureVac NV (CVAC) does not currently pay a regular dividend.

What is CVAC's market cap?

CureVac NV (CVAC) has a market capitalization of $1.05B with a current stock price of $4.66.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In